Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

BACKGROUND: A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. METHODS: This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. FINDINGS: Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0-75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4-97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8-80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3-4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. INTERPRETATION: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials. FUNDING: UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, Bill & Melinda Gates Foundation, Lemann Foundation, Rede D'Or, Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Background A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. Methods This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. Findings Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0–75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4–97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8–80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3–4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. Interpretation ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials

Análise espaço-temporal do uso da terra em parte do semi-árido cearense Spatial and temporal-time analysis of land use in part of the semi-arid region of Ceará State, Brazil

A cobertura vegetal exerce papel imprescindível à proteção e conservação dos recursos naturais, principalmente no que diz respeito aos solos. Este estudo teve como objetivo avaliar e analisar a dimensão espacial e temporal da ação antrópica na cobertura vegetal de parte do semi-árido cearense, utilizando imagens LANDSAT TM-5, de 1985 e 1994, e técnicas de geoprocessamento, para verificar a hipótese de que a degradação ambiental vem sendo intensificada. Foram confeccionadas cartas de vegetação, uso da terra, solos e hidrografia, obtendo-se cartas de sobreposição, por meio das quais se constatou o aumento de áreas degradadas nas diferentes unidades fitoecológicas. No período de uma década, comprovou-se o processo progressivo da degradação nas áreas dos municípios de Independência, Pedra Branca, Mombaça e Tauá, tendo as áreas do município de Pedra Branca apresentado menor degradação. A unidade fitoecológica mais degradada, dentre as estudadas, foi a Caatinga Arbórea Aberta, desencadeando processos de degradação e transformação das unidades circunvizinhas. Grande parte da área foi atingida por processos de degradação ambiental, com forte pauperização da biodiversidade, acompanhados por um rebaixamento geral das formações vegetais.<br>The vegetation cover plays a key role in protection and conservation of natural resources, particularly concerning soils. This study had as objective to analyze space and time dimensions of anthropic influence on the vegetation cover in part of the semi-arid region of the Ceará State, Brazil. LANDSAT TM-5 satellite images of 1985 and 1994 combined with geoprocessing techniques were used to verify the hypothesis of intensification of environmental degradation. Maps of the vegetation cover, land use, soils, and hydrography were elaborated. They pointed out to an increase in degraded areas of the different phytoecological units. During this decade, a progressive degradation process was verified in study areas of the Independência, Pedra Branca, Mombaça and Tauá counties The Pedra Branca areas suffered the least from degradation. Among all areas, the sparse arborous Caatinga was the most degraded ecological unit, triggering degradation and transformation processes in the neighboring units. A large part of the area under investigation was environmentally degraded, with a substantial reduction of biodiversity, besides an overall downsizing of vegetal formations

Physico-chemical and harvest time alterations in pineapple fruits ‘Smooth Cayenne’ caused by paclobutrazol

The aim of this work was to assess the effect of an inhibitor acting in the floral differentiation on the physico-chemical characteristics of pineapple fruits and on the effect in the harvest time. Paclobutrazol was used at concentrations of 100, 150, and 200 mg L-1, applied 2, 3 or 4 times in ‘Smooth Cayenne’ pineapple plants. The treatment did not influence the chemical characteristics of the fruits, and even having some physical alterations, they were within the quality standard for the commercialization. The harvest time was amplified in all the treatments comparing to the control. However, 150 mg L-1 applied twice promoted the best result when analyzing together the harvest time and the fruit fresh matter.<br>O objetivo deste trabalho foi avaliar o efeito de um inibidor da diferenciação floral nas características físico-químicas dos frutos do abacaxizeiro, bem como, no período de colheita. Utilizou-se paclobutrazol a 100, 150 e 200 mg L-1 aplicados 2, 3 ou 4 vezes, em plantas de abacaxi cv. Smooth Cayenne. Os tratamentos não influenciaram nas características químicas dos frutos, e mesmo alterando algumas características físicas, os frutos permaneceram dentro dos padrões de qualidade para comercialização. O período de colheita foi ampliado em todos os tratamentos comparando-se com o controle, porém, 150 mg L-1 aplicados 2 vezes promoveu melhor resultado analisando-se em conjunto a época de colheita com a massa fresca do fruto